September 2013

TreatmentTrends®: Multiple Sclerosis (US) Q3 2013


BioTrends Research Group is pleased to announce the continuation of TreatmentTrends®: Multiple Sclerosis (US) report series in 2013. Each biannual report examines the current trends in the management of multiple sclerosis (MS) from the perspective of neurologists.
TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends® evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.

Questions Answered in This Report:

  *   Understand the relative MS patient load by disease classification (CIS, RRMS, PRMS, SPMS, PPMS) and how DMAs are used in each group

  *   Understand product attributes that are most important to neurologists when selecting DMAs and compare the different brands on how they are perceived to perform against each attribute

  *   Understand how the use of each DMA brand is expected to change in the next six months and what factors are driving those trends

  *   Evaluate sales strategies and messaging efforts of DMA therapies

  *   Assess awareness of and interest in DMA therapies that are in late stage development


Sample Frame & Methodology:

~100 neurologists complete a 45 minute online quantitative survey with several open ended questions for qualitative feedback

To qualify, respondents meet the following criteria:

- Minimum of 20 patients with relapsing remitting multiple sclerosis under management

- Have been in practice a minimum of 2 years and a maximum of 35 years

- More than 75% of professional time spent in clinical practice


- Final report in powerpoint format

- Tracking between waves will be provided for clients purchasing the report series

- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request

- Proprietary question slide deck and frequency tables

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each wave

Product Coverage:

- Approved: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Rebif, Tysabri, Ampyra

- In development: Copaxone 40mg 3x weekly, daclizumab, laquinimod, Lemtrada, ocrelizumab, PEG-Avonex, Tecfidera

Related 2013 Reports:

- TreatmentTrends®: Multiple Sclerosis (EU)

- LaunchTrends®: Aubagio (US)

- LaunchTrends®: Lemtrada (US)

- LaunchTrends®: Tecfidera (US)

- DecisionBase®: Multiple Sclerosis-Chronic Progressive

- DecisionBase®: Multiple Sclerosis-Relapsing Remitting

- PatientBase®: Multiple Sclerosis in Mexico

- PatientBase®: Multiple Sclerosis in Turkey

- PatientBase®: Multiple Sclerosis in South Korea

- Treatment Algorithms®: Multiple Sclerosis

- Pharmacor®: Multiple Sclerosis

- Physician and Payer Forum®: Multiple Sclerosis

Search Published Reports

Decision Resources Group brands include: